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The increasing awareness of the high prevalence of cardiovas- It is important to note, however, that there are multiplecular disease (CVD) in the dialysis population has led clinical
risk factors for any of one of these CV events includingnephrologists and researchers to focus their attention on pro-
metabolic derangements (familial and acquired dyslipi-cesses and factors that are present in patients prior to dialysis.
It is clear that many of the risk factors for kidney disease and demias), endocrine abnormalities (diabetes and hyper/
cardiovascular disease are similar: This may account for the hypothyroidism), and hypercoagulable states, in addition
high prevalence of CVD within the dialysis population. How- to hypertension and smoking. Thus the identification ofever, it is evident that there are unique risk factors for CVD
a specific event does not necessarily imply a specificthat are present in patients with chronic kidney disease (CKD).
etiology. Where possible, we could employ a dichoto-These unique uremia-related risk factors for CVD include ane-
mia, hyperparathyroidism, abnormalities of mineral metabo- mous classification system for CVD. Simplistically, car-
lism, and acidosis. Of note, the association of anemia, or lower diac disease can be caused by disorders of perfusion (e.g.,
levels of hemoglobin, have been consistently described in all
atherosclerotic disease leading to CAD and ischemicpopulations with kidney disease. Left ventricular hypertrophy
damage) or disorders of cardiac structure and functionhas long been known as an independent risk factor for death
and CV events, in both the dialysis and general populations. (e.g., LVH, valvular heart disease, congenital heart dis-
There have been accumulating data that LVH and left ventricu- ease). These two disorders can certainly occur together,
lar (LV) growth occur prior to dialysis in patients with kidney or one can exacerbate the other (i.e., in the presence of
disease, and that the prevalence of LVH in that group of pa-
CAD, the growth of the left ventricular mass may leadtients is caused by, conventional risk factors for LVH (e.g.,
to problems with ischemia with increased demand; Fig.hypertension) as well as nonconventional risk factors such as
anemia. [1, 2, 3, 4]. 1). The risk factors for the different types of cardiac
disease may be different, however. For example, disor-
ders of perfusion/atherosclerotic processes may be caused
The focus of this article is to review the literature that by diabetes, dyslipemidias, and smoking, whereas disor-
supports the role of anemia in the development to left ders of pump structure and function may be due to hyper-
ventricular hypertrophy (LVH), and the propagation of tension, anemia, and abnormalities of calcium and phos-
cardiovascular disease (CVD) in patients with kidney dis- phate (common in patients with kidney disease). Thus,
ease, with specific emphasis on data pertaining to those although heart disease is common in patients with kidney
patients prior to dialysis therapy. disease (75% commencing dialysis have LVH) [5], not all
cardiac disease in chronic kidney disease (CKD) patients
is caused by conventional or atherosclerotic processes,THE SPECTRUM OF CVD
nor is all disease due to ischemic damage [6].
Cardiovascular disease can be broadly defined as dis- LVH is categorically defined as an LV mass index
ease affecting the heart or blood vessels supplying major
131 g/m2 in males, and 100 g/m2 in females, based on
organs. Most studies define cerebrovascular (CV) dis- population data. However, LV mass is actually a continu-
ease or events to include episodes of congestive heart ous variable, and thus this classification of LVH is some-
what arbitrary. Importantly, there are different types of
LV hypertrophy or growth including eccentric dilation,Key words: anemia, blood hemoglobin, LVH disease, cardiovascular
disease. concentric remodeling, and concentric hypertrophy. The
processes may occur together. The resultant product of 2002 by the International Society of Nephrology
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with the above findings that Hgb and systolic blood pres-
sure are associated with LVH [1, 2]. Furthermore, in the
literature it is evident that lower Hgb or a fall in hemoglo-
bin of modest proportions is associated with more hospi-
talizations, and with a change in NYHA classification for
heart failure [2, 11]. Other authors have demonstrated
similar associations between Hgb and hospitalizations in
patients with CKD prior to dialysis. [12].
TREATMENT OF ANEMIA AND CORRECTION
OF CARDIAC DISEASE
There have been a number of small, nonrandomized
studies that have described the improvement of cardiac
parameters with correction of anemia in patients with
CKD, and fewer that have evaluated LVH regression or
Fig. 1. Demonstrates a schematic representation of cardiac disease, cardiac disease in patients on dialysis. In patients withdichotomously characterized as disorders of perfusion and pump func-
CKD, prior to dialysis, it appears that regression of LVMItion. Traditional and uremic risk factors are shown as preferentially
affecting one or the other. See text for details. Adapted from Parfrey is possible [13–15], and that improvement of symptoms
(reference 6) and personal communication. of heart failure is possible [16]. In patients on dialysis,
studies in which anemia has been corrected have led to
different results depending on the population studied.
In the Besarab study [17], in which patients with severethese processes is the remodeling of the myocardium
heart disease were entered into the study to normalizethrough both hypertrophy of existing myofibrils, and re-
hemoglobin, those in the treatment group had a higheralignment of the sacromeres. Risk factors for concentric
probability of death, and the study was stopped early.hypertrophy include hypertension (or other conditions
In the Canadian normalization of Hgb study, the correc-associated with pressure overload), and age, whereas
tion of anemia in patients with LVH but no evidence ofeccentric hypertrophy is often due to conditions in which
symptomatic heart disease did not lead to any increasethere is volume overload (e.g., anemia, AV fistulae).
in morbidity or mortality; However, the authors wereThus it is clear that in patients with kidney disease, expo-
also not able to demonstrate a significant impact on es-sure to both pressure and volume overload may contrib-
tablished LVH [18].ute to LVH.
Taken together, these studies suggest that the correc-
tion of Hgb to reverse established or severe cardiac dis-
ASSOCIATION BETWEEN LVH, HEART ease in patients on dialysis is less likely to be of major
FAILURE, AND CKD POPULATIONS benefit. However, the data in the CKD group, prior
to dialysis in conjunction with the data from dialysisSince the early 1990s, there have been consistent reports
of heart disease in dialysis patients, and especially the high populations, does suggest that the appropriate time to
intervene with respect to Hgb management is prior toprevalence of LVH in dialysis groups [3, 5, 7]. Of key
importance is the finding that 50% of deaths in dialysis dialysis. It may well be that the effect of sustained lower
Hgb levels, in conjunction with exposure to the uremicpatients are caused by CVD, the most common of which
is heart failure. Indeed, Parfrey et al have shown that the milieu, which includes middle molecules, acidosis, abnor-
malities of mineral metabolism, and high levels of knownprobability of de novo heart failure after starting dialysis
is in the order of 80% within the first year, and that the growth factors (including but not limited to iPTH, angio-
tensin II, insulin-derived GF, platelet-derived GF, andpresence of both chronic heart failure (CHF) and LVH
predict poorer survival. Predictors of both CHF and TGF-beta), leads to irreversible myocardial changes in
structure and function [19–22]. Thus, the identificationLVH include age, hypertension and serum hemoglobin
(Hgb) levels [5, 7–9]. and treatment of Hgb early in the course of kidney dis-
ease may be of utmost importance if we are to changeReview of data from the transplant population, re-
cently published by Rigatto et al, demonstrates a similar the outcome of patients once they start dialysis.
Of interest, we have recently completed an analysisrelationship between new onset CHF and Hgb levels
in the post-transplant patient, as well as a relationship that reviews the impact of various risk factors on progres-
sion to ESRD. Importantly, both the presence of lowbetween hemoglobin level and LVH [10].
Data in patients prior to dialysis, published by Levin hemoglobin and the presence of CVD independently
predict shortened time to renal replacement therapyand co-workers, in two independent cohorts, is consistent
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this article to review these in detail, but the processes
can be summarized as follows: In all people with anemia,
maintenance of adequate tissue oxygenation is achieved
by both non-hemodynamic and hemodynamic adapta-
tions. Non-hemodynamic adaptations include increases
in erythropoietin production and increases in the intra-
erythrocytic concentrations of 2,3-diphosphoglycerate
(2,3-DPG) [23]. Hemodynamic adaptations begin to oc-
cur when hemoglobin concentrations decline to100 g/L
or, notably, in non-resting conditions at hemoglobin con-
centrations between 100 and 140 g/L. Briefly, such adap-
tations include an increase in cardiac preload and a de-
creased systemic vascular resistance leading to decreased
afterload, both of which contribute to the high cardiac
output state. Although the cardiovascular responses are
appropriate, long-term activation leads to LV remodel-Fig. 2. Demonstrates the prevalence of hemoglobin values at level of
ing including initial dilation from the increase in preload,kidney function, estimated by CCr, in a cohort of patients prior to dialysis.
Upper limit of hemoglobin selected is 13, which is below the level of with subsequent hypertrophy in an attempt to decrease
hemoglobin that defines anemia according to World Health Organiza- the high wall tension of the dilated LV. In the non-tion. The prevalence of anemia increases at each lower level of kidney
kidney disease population, these changes are frequentlyfunction, with the prevalence reaching 87% in the lowest group.
Adapted from Levin et al [2]. reversible. However, in patients with CKD, the response
to anemia may be altered compared with that of the gen-
eral population. Although erythropoietin production does
rise as the hemoglobin falls, the rise is not as high as(RRT) [11]. Thus, the aggressive treatment of CKD pa-
expected for the degree of anemia. The relative failure oftients with respect to their traditional CVD risk factors,
erythropoietin production is linked to loss of kidney mass.and the uremia-related risk factors (e.g., Hgb) may to-
Because uremia is a hypermetabolic state [24], it is pos-gether reduce the burden of illness in these patients. The
sible that hemodynamic changes in response to anemiacompletion of large multinational studies currently in
may occur at higher hemoglobin concentrations than inprogress will undoubtedly improve our understanding of
the non-chronic kidney disease cohort. It is certainlythe contribution of aggressive treatment strategies.
plausible that the heart, in a hypermetabolic milieu, is
more susceptible to the hemodynamic effects of anemia.
DEFINING ANEMIA AND ITS PREVALENCE Supporting this hypothesis is animal evidence that hearts
IN CKD POPULATIONS of uremic rats are more vulnerable to ischemic damage
Importantly, the definition of anemia according to secondary to rapid degradation of energy-rich nucleo-
World Health Organization (WHO) is130 g/L in males tides and diminished expression of insulin-sensitive glu-
and postmenopausal females, and  120 g/L in females. cose transporter (abstract; Matthais et al, J Am Soc
By this strict definition, the majority of all dialysis pa- Nephrol 6:1023, 1995) [25]. Furthermore, in contrast to
tients are anemic. Traditionally, renal anemia has been the general population, there are other potential contrib-
defined as a hemoglobin level below 100 g/L, and much utors to the development of cardiac disease in patients
treatment has been aimed at target levels between 110 with CKD. Hypertension, volume expansion, diabetes,
and 120 g/L. Analysis of Canadian mutlicenter cohort hyperparathyroidism, and uremia, in addition to anemia,
data suggests the prevalence of anemia defined using all contribute to the high prevalence of LVH observed
in CKD. Moreover, the presence of these co-morbid con-WHO or ‘traditional’ renal literature definitions is very
high at all levels of GFR (Fig. 2). This is confirmed in ditions contributes to myocardial fibrosis, calcium depo-
sition, increased LV stiffness, and arteriosclerosis that isan independent population, using population-based data
from NHANES III: The prevalence of anemia increases commonly observed in the hearts of patients with CKD.
It is the chronic exposure to these maladaptive processesat levels of GFR 60 mL/m, again affirming the relation-
ship of anemia and kidney function (Astor et al, in press, that likely prevents the reversibility of LVH in uremic
individuals, and that may well amplify the effect of ane-Archives of Internal Medicine, 2002).
mia on heart function.
THE PATHOPHYSIOLOGY OF ANEMIA AND
HEART DISEASE CONCLUSION
The prevalence of cardiovascular disease in patientsThere are both direct and indirect effects of anemia
on heart function and growth. It is beyond the scope of with CKD at all stages is higher than that of the general
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